Neutrophil-lymphocyte ratio is prognostic in early stage resected small-cell lung cancer.

Background: For selected early stage small cell lung cancer (SCLC), curative intent surgery is often performed. Previous studies, predominantly from East Asia, reported that high neutrophil to lymphocyte ratio (NLR), and platelet-lymphocyte ratio (PLR) correlate with poor prognosis in several types of tumors including SCLC. Our aim was to investigate the prognostic value of NLR and PLR in Caucasian patients with resected SCLC, as potential tool to select patients for multimodal treatment including surgery.

Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP).

Background: The objectives of this study were to evaluate the safety profile of aflibercept and health-related quality of life (HRQL) in patients with metastatic colorectal cancer (mCRC) provided with aflibercept access before marketing authorization.

Patients And Methods: Patients received aflibercept followed by FOLFIRI (fluorouracil, leucovorin, irinotecan) on day 1 of a 2-week cycle until disease progression, unacceptable toxicity, death, or patient/investigator decision to discontinue. Treatment-emergent adverse events (TEAEs) were evaluated, and HRQL was assessed at baseline, cycle 3, and every other cycle using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, EORTC QLQ-CR29, and EuroQol 5-Dimensions 3-Levels questionnaires (NCT01571284).

International consensus on a complications list after gastrectomy for cancer.

Background: Perioperative complications can affect outcomes after gastrectomy for cancer, with high mortality and morbidity rates ranging between 10 and 40%. The absence of a standardized system for recording complications generates wide variation in evaluating their impacts on outcomes and hinders proposals of quality-improvement projects. The aim of this study was to provide a list of defined gastrectomy complications approved through international consensus.

Registry of gastric cancer treatment evaluation (REGATE): I baseline disease characteristics.

Aims: A better understanding of treatment patterns and outcomes in different countries should improve the management of patients with gastric cancer globally. The REgistry of GAstric Cancer Treatment Evaluation (REGATE) study was established to evaluate variations in gastric cancer disease characteristics and treatment patterns in different parts of the world.

Methods: REGATE was a prospective international registry enrolling patients with newly diagnosed gastric cancer at any stage of the disease.

Registry of gastric cancer treatment evaluation (REGATE): II treatment practice.

Aims: The objective of the registry of gastric cancer treatment evaluation (REGATE) study was to evaluate approaches to gastric cancer treatment in different geographical regions.

Methods: REGATE enrolled patients with newly diagnosed gastric cancer at any stage of the disease from the Asia-Pacific region, Europe, the Indian subcontinent, Latin America and North Africa between 2004 and 2008.

Results: Among 9965 patients, 69% received surgery, 40% palliative care, 29% adjuvant therapy and 2% neoadjuvant therapy; 15% received no treatment.